Urology

Top Medical News
High dairy food intake ups risk of prostate cancer
Yesterday
Men who regularly consume dairy foods are more likely to develop prostate cancer than those with a lower level of consumption, a prospective cohort study has found.
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
Audrey Abella, 4 days ago
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Sexual dysfunction common among bladder cancer patients
04 Aug 2022
Patients with bladder cancer suffer from high rates of sexual dysfunction, especially those who have undergone radical treatments, a recent study has found.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
Audrey Abella, 04 Aug 2022
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Patients prefer being awake but sedated during urologic procedures
Elvira Manzano, 04 Aug 2022
Patients prefer conscious sedation over general anaesthesia (GA) during urologic procedures, according to Canadian researchers who followed patients undergoing various endourologic, ureteric, urethral, or advanced cystoscopic procedures.
drug, clinical, medicine, aspirin, warfarin, insulin, metformin, nitroglycerin
03 Aug 2022
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a drug class mainly used for the management of type 2 diabetes, significantly reduces serum uric acid (SUA) concentration, a recent study has shown.
Low-intensity shock wave safe, effective on moderate erectile dysfunction
02 Aug 2022
Men with moderate erectile dysfunction (ED) may benefit from having 12 sessions of low-intensity shock wave therapy (SWT) twice weekly for 6 weeks, with a treatment protocol of 5,000 impulses, 0.0096 mJ/mm2 energy flux density, and 5-Hz frequency, suggests a study.
Special Reports
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Conference Reports
Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
Audrey Abella, 08 Aug 2022
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
Audrey Abella, 04 Aug 2022
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Patients prefer being awake but sedated during urologic procedures
Elvira Manzano, 04 Aug 2022
Patients prefer conscious sedation over general anaesthesia (GA) during urologic procedures, according to Canadian researchers who followed patients undergoing various endourologic, ureteric, urethral, or advanced cystoscopic procedures.
Which drugs raise risk of urinary tract infections?
Stephen Padilla, 29 Jul 2022
Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
Jairia Dela Cruz, 28 Jul 2022
Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).
Verapamil reduces penile curvature, plaque size in Peyronie’s disease
Stephen Padilla, 28 Jul 2022
Use of the calcium channel blocker verapamil is both safe and effective for the treatment of Peyronie’s disease, as proven by a decrease in penile curvature, reduction in plaque size, and improvement in erectile dysfunction, with minimal to mild side effects, relative to placebo, according to the results of a systematic review and meta-analysis.
Short-course quinolones, pivmecillinam on par with standard regimens in uncomplicated cystitis
Jairia Dela Cruz, 27 Jul 2022
For women with acute uncomplicated cystitis, treatment regimens that include third- and fourth-generation quinolones and pivmecillinam can be administered in shorter courses, which perform similarly to the currently recommended regimens in terms of achieving symptomatic cure, according to the results of a meta-analysis presented at the 37th Annual European Association of Urology (EAU) Congress.